These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 28655978)

  • 1. Early effect on intragastric pH of oral administration of rabeprazole with mosapride compared with rabeprazole alone.
    Iida H; Kaai M; Inoh Y; Kanoshima K; Ohkuma K; Nonaka T; Fujita K; Ida T; Kusakabe A; Maeda S; Nakajima A; Inamori M
    Ann Gastroenterol; 2017; 30(4):424-428. PubMed ID: 28655978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early effect of oral administration of omeprazole with mosapride as compared with those of omeprazole alone on the intragastric pH.
    Iida H; Inamori M; Fujii T; Sekino Y; Endo H; Hosono K; Nonaka T; Koide T; Takahashi H; Yoneda M; Goto A; Abe Y; Kobayashi N; Kirikoshi H; Kubota K; Saito S; Gotoh E; Maeda S; Nakajima A
    BMC Gastroenterol; 2012 Mar; 12():25. PubMed ID: 22448810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early effects of oral administration of lafutidine with mosapride compared with lafutidine alone on intragastric pH values.
    Iida H; Inamori M; Nozaki Y; Endo H; Hosono K; Akiyama T; Sakamoto Y; Takahashi H; Koide T; Tokoro C; Abe Y; Nakajima A
    BMC Gastroenterol; 2009 Jul; 9():52. PubMed ID: 19589146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of esomeprazole and rabeprazole on intragastric pH in healthy Chinese: an open, randomized crossover trial.
    Li ZS; Zhan XB; Xu GM; Cheng NN; Liao Z
    J Gastroenterol Hepatol; 2007 Jun; 22(6):815-20. PubMed ID: 17565634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
    Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
    J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use?
    Inamori M; Togawa J; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Shimamura T; Kubota K; Sakaguchi T; Saito S; Ueno N; Nakajima A
    J Gastroenterol; 2005 May; 40(5):453-8. PubMed ID: 15942709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects.
    Armstrong D; James C; Camacho F; Chen Y; Horbay GL; Teixeira B; Husein-Bhabha FA
    Aliment Pharmacol Ther; 2007 Jan; 25(2):185-96. PubMed ID: 17116123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative bioavailability of a 5 mg mosapride/10 mg rabeprazole fixed dose combination tablet versus separate single tablets in healthy volunteers: a single-dose randomized open-label crossover study.
    Keller GA; Czerniuk P; Bertuola R; de Mena F; Simoni MV; Assefi AR; Di Girolamo G
    Curr Med Res Opin; 2011 Nov; 27(11):2203-11. PubMed ID: 21970660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
    Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
    Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
    Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
    Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo.
    Williams MP; Usselmann B; Chilton A; Sercombe J; Nwokolo CU; Pounder RE
    Aliment Pharmacol Ther; 2003 Mar; 17(6):775-83. PubMed ID: 12641499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers.
    Dammann HG; Burkhardt F; Wolf N
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1195-203. PubMed ID: 10468701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
    Wilder-Smith CH; Röhss K; Nilsson-Pieschl C; Junghard O; Nyman L
    Digestion; 2003; 68(4):184-8. PubMed ID: 14691345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection.
    Ohning GV; Barbuti RC; Kovacs TO; Sytnik B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 2000 Jun; 14(6):701-8. PubMed ID: 10848652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers.
    Morelli G; Chen H; Rossiter G; Rege B; Lu Y
    Aliment Pharmacol Ther; 2011 Apr; 33(7):845-54. PubMed ID: 21272047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects.
    Williams MP; Blanshard C; Millson C; Sercombe J; Pounder RE
    Aliment Pharmacol Ther; 2000 Jun; 14(6):691-9. PubMed ID: 10848651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers.
    Röhss K; Wilder-Smith C; Nauclér E; Jansson L
    Clin Drug Investig; 2004; 24(1):1-7. PubMed ID: 17516685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ascending single-dose safety and tolerance study of an oral formulation of rabeprazole (E3810).
    Lew EA; Barbuti RC; Kovacs TO; Sytnic B; Humphries TJ; Walsh JH
    Aliment Pharmacol Ther; 1998 Jul; 12(7):667-72. PubMed ID: 9701531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
    Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.